Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 4/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 7/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31014572 | 0.84 | RAB9A (0.46) | NPC1RAB9ASMN1; SMN2RIPK2CHRNB2 | |
| SCHEMBL19947421 | 0.79 | KDM4E (0.44) | SMN1; SMN2RIPK2CHRNB2CHRNA4CYP11B1 | |
| SCHEMBL19984470 | 0.77 | RIPK2 (0.46) | NPC1RAB9ASMN1; SMN2RIPK2CHRNB2 | |
| SCHEMBL24921189 | 0.76 | CYP11B1 (0.52) | RIPK2CHRNB2CHRNA4CYP11B1CYP11B2 | |
| SCHEMBL30240891 | 0.72 | CYP11B1 (0.45) | CYP11B1CYP11B2ROCK2ROCK1 | |
| SCHEMBL31015139 | 0.71 | RIPK2 (0.49) | NPC1RAB9ASMN1; SMN2RIPK2CYP11B1 | |
| SCHEMBL31015304 | 0.71 | CYP11B1 (0.43) | NPC1RAB9ASMN1; SMN2RIPK2CHRNB2 | |
| SCHEMBL31015116 | 0.70 | RIPK2 (0.51) | NPC1RAB9ASMN1; SMN2RIPK2CYP11B1 | |
| SCHEMBL27163243 | 0.70 | DRD4 (0.55) | RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL19959123 | 0.69 | RIPK2 (0.39) | RIPK2CHRNB2CHRNA4CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002475-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | EPICS THERAPEUTICS (BE) | 2025-01-02 | — | — | US | disclosed |
| US-12091400-B2 | Piperidine derivatives as METTL3 inhibitors | EPICS THERAPEUTICS (BE) | 2024-09-17 | — | — | US | disclosed |
| US-20240270716-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | EPICS THERAPEUTICS (BE) | 2024-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270716-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | METTL3, METTL16, DIMT1 | NPC1 1608/4885RAB9A 2062/4885SMN1; SMN2 1639/4885 |
| US-20250002475-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | METTL3, METTL16, DIMT1 | NPC1 1608/4885RAB9A 2062/4885SMN1; SMN2 1639/4885 |
| US-12091400-B2 | Piperidine derivatives as METTL3 inhibitors | METTL3, METTL16, DIMT1 | NPC1 1608/4885RAB9A 2062/4885SMN1; SMN2 1639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.